 |
|
Bromocriptine Reduces Growth Hormone in Acromegaly
Patrick M. Bell, MD, MRCP;
A. Brew Atkinson, MD, MRCP;
David R. Hadden, MD, FRCP;
Laurence Kennedy, MD, MRCP;
Hilary Leslie, MS;
J. Desmond Merrett, PhD;
Brian Sheridan, MS
Arch Intern Med. 1986;146(6):1145-1149.
Abstract
• We assessed serum growth hormone (GH) levels in ten patients with acromegaly during a 24-hour profile and a 75-g oral glucose tolerance test (GTT). Serum GH levels were measured after five weeks of bromocriptine mesylate therapy, 20 mg daily (P1), after five weeks without bromocriptine mesylate therapy (P2), and again five weeks following restarting treatment with bromocriptine, 20 mg daily (P3). During the 24-hour profile, the following occurred: (1) mean serum GH level of the group was lower during P1 (20.5 mU/L) and P3 (20.8 mU/L) than P2 (49.6 mU/L); (2) in six individual patients during P1 and P3, there was a significant reduction in the mean serum GH value; and (3) a marked circadian variation in the serum GH value was present both with and without the drug therapy in five patients. During the GTT, the mean serum GH value was lower during P1 (18.4 mU/L) and P3
Author Affiliations
From the Sir George E. Clark Metabolic Unit (Drs Bell, Atkinson, Hadden, and Kennedy) and the Regional Endocrine Laboratory (Ms Leslie and Mr Sheridan), Royal Victoria Hospital, and the Department of Medical Computing and Statistics, Queen's University of Belfast, Institute of Clinical Science (Dr Merrett), Belfast.
Footnotes
Accepted for publication Sept 5, 1985.
Reprint requests to Sir George E. Clark Metabolic Unit, Royal Victoria Hospital, Belfast BT12 6BA, Northern Ireland (Dr Atkinson).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
|
